NEW YORK — The US Food and Drug Administration on Tuesday granted separate Emergency Use Authorizations for PCR-based SARS-CoV-2 tests developed by Biomeme and LumiraDx.
The Biomeme SARS-CoV-2 Real-Time RT-PCR Test is designed to detect the virus' ORF1ab and S genes in nasopharyngeal, nasal, and oropharyngeal swab specimens, as well as nasopharyngeal wash/aspirate or nasal aspirate specimens.